NASDAQ:MCRB

Seres Therapeutics - MCRB Stock Forecast, Price & News

$5.69

+0.02 (+0.35%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $5.49
▼
$5.71
50-Day Range: $4.95
▼
$6.09
52-Week Range: $2.50
▼
$9.49

Volume: 863,994 shs
Average Volume: 1.25 million shs
Market Capitalization: $717.40 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.25

Institutional Ownership

Seres Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 185.6% Upside
$16.25 Price Target
Short Interest: Bearish
6.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.14
Upright™ Environmental Score
News Sentiment: 1.06
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.08) to ($1.62) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

422nd out of 1,005 stocks

Pharmaceutical Preparations Industry

194th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Seres Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.25, Seres Therapeutics has a forecasted upside of 185.6% from its current price of $5.69.
Amount of Analyst Coverage
Seres Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.20% of the outstanding shares of Seres Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Seres Therapeutics has a short interest ratio ("days to cover") of 9.9.
Change versus previous month
Short interest in Seres Therapeutics has recently increased by 8.91%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Seres Therapeutics does not currently pay a dividend.
Dividend Growth
Seres Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Seres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Seres Therapeutics is -1.14.

3.9

News and Social Media Coverage

News Sentiment
Seres Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Seres Therapeutics this week, compared to 1 article on an average week.
Search Interest
52 people have searched for MCRB on MarketBeat in the last 30 days. This is an increase of 940% compared to the previous 30 days.
MarketBeat Follows
5 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seres Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Seres Therapeutics is held by insiders.
Percentage Held by Institutions
90.16% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Seres Therapeutics are expected to decrease in the coming year, from ($1.08) to ($1.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Seres Therapeutics has a P/B Ratio of 63.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Seres Therapeutics (NASDAQ:MCRB) Stock

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Stock News Headlines

March 25, 2023 | americanbankingnews.com

Seres Therapeutics (NASDAQ:MCRB) Shares Down 4.9%

March 24, 2023 | americanbankingnews.com

Canaccord Genuity Group Boosts Seres Therapeutics (NASDAQ:MCRB) Price Target to $15.00

March 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

March 9, 2023 | finance.yahoo.com

Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

March 9, 2023 | finance.yahoo.com

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript

March 8, 2023 | markets.businessinsider.com

Where Seres Therapeutics Stands With Analysts

March 8, 2023 | finance.yahoo.com

Q4 2022 Seres Therapeutics Inc Earnings Call

March 7, 2023 | finance.yahoo.com

Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates

March 26, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 7, 2023 | msn.com

Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62M

March 7, 2023 | finance.yahoo.com

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 6, 2023 | msn.com

Seres Therapeutics Earnings Preview

February 28, 2023 | finance.yahoo.com

Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023

February 27, 2023 | finance.yahoo.com

Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

February 14, 2023 | finance.yahoo.com

Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

February 8, 2023 | finance.yahoo.com

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

January 28, 2023 | finance.yahoo.com

Seres Therapeutics' (NASDAQ:MCRB) investors will be pleased with their respectable 70% return over the last three years

January 13, 2023 | finance.yahoo.com

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 5, 2023 | finance.yahoo.com

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

January 4, 2023 | finance.yahoo.com

Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 1, 2023 | forbes.com

Seres Therapeutics

November 22, 2022 | finance.yahoo.com

Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

November 10, 2022 | seekingalpha.com

Seres Gets Closer To Good Times

November 8, 2022 | finance.yahoo.com

Seres Therapeutics Third Quarter 2022 Earnings: Misses Expectations

November 2, 2022 | seekingalpha.com

Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call Transcript

October 27, 2022 | finance.yahoo.com

Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

October 26, 2022 | finance.yahoo.com

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MCRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MCRB Company Calendar

Last Earnings: 11/10/2021
Today: 3/26/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MCRB
CUSIP: N/A
CIK: 1609809
Web: www.serestherapeutics.com
Phone: (617) 945-9626
Fax: N/A
Employees: 333
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.25
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +185.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-250,160,000.00
Net Margins: -3,509.50%
Pretax Margin: -3,509.50%
Return on Equity: -548.64%
Return on Assets: -79.81%

Debt

Debt-to-Equity Ratio: 4.69
Current Ratio: 2.28
Quick Ratio: 2.28

Sales & Book Value

Annual Sales: $7.13 million
Price / Sales: 100.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.09 per share
Price / Book: 63.22

Miscellaneous

Outstanding Shares: 126,080,000
Free Float: 120,781,000
Market Cap: $717.40 million
Optionable: Optionable
Beta: 2.70

Key Executives

Eric D. Shaff
President, Chief Executive Officer & Director

Marcus Chapman
Senior Vice President-Operations

David A. Arkowitz
EVP, Chief Financial & Accounting Officer

Matthew R. Henn
Chief Scientific Officer & Executive VP

Barbara McGovern
Vice President-Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MCRB Stock - Frequently Asked Questions

Should I buy or sell Seres Therapeutics stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares.
View MCRB analyst ratings or view top-rated stocks.
What is Seres Therapeutics' stock price forecast for 2023?: 5 brokerages have issued 12-month price targets for Seres Therapeutics' shares. Their MCRB share price forecasts range from $12.00 to $25.00. On average, they anticipate the company's stock price to reach $16.25 in the next twelve months. This suggests a possible upside of 185.6% from the stock's current price.
View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts.
How have MCRB shares performed in 2023?: Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB shares have increased by 1.6% and is now trading at $5.69.
View the best growth stocks for 2023 here.
When is Seres Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MCRB earnings forecast.
How were Seres Therapeutics' earnings last quarter?: Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of ($0.47) by $1.19. The biotechnology company earned $126.73 million during the quarter, compared to the consensus estimate of $7.12 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 548.64% and a negative net margin of 3,509.50%. During the same period last year, the firm earned ($0.36) earnings per share.
What ETFs hold Seres Therapeutics' stock?: ETFs with the largest weight of Seres Therapeutics (NASDAQ:MCRB) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB).
What other stocks do shareholders of Seres Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?: (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
What is Seres Therapeutics' stock symbol?: Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
Who are Seres Therapeutics' major shareholders?: Seres Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Eversept Partners LP (1.77%), Geode Capital Management LLC (1.28%), Point72 Asset Management L.P. (0.56%), Jennison Associates LLC (0.54%), Charles Schwab Investment Management Inc. (0.51%) and JPMorgan Chase & Co. (0.49%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional.
View institutional ownership trends.
How do I buy shares of Seres Therapeutics?: Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seres Therapeutics' stock price today?: One share of MCRB stock can currently be purchased for approximately $5.69.
How much money does Seres Therapeutics make?: Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $717.40 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis.
How many employees does Seres Therapeutics have?: The company employs 333 workers across the globe.
How can I contact Seres Therapeutics?: Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com.

This page (NASDAQ:MCRB) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Seres Therapeutics - MCRB Stock Forecast, Price & News

Seres Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Seres Therapeutics (NASDAQ:MCRB) Stock

MCRB Stock News Headlines

MCRB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MCRB Stock - Frequently Asked Questions

Overall MarketRank^™